News
GSK and Alector ink neurodegenerative diseases partnership
British drugmaker GlaxoSmithKline (GSK) has announced a new global collaboration with Alector to develop and commercialise two monoclonal antibodies (mAb) for the treatment of neurodegenerative diseases.